Melanotan I Dosage Guide

Dosage overview

Dosing notes

Scenesse is administered as a subcutaneous implant by a healthcare provider, not self-injected. The implant slowly releases afamelanotide over approximately 60 days. Available through specialty pharmacies only. Research peptide versions are also available as lyophilized powder for subcutaneous injection, but these are not FDA-approved formulations.

FDA-approved indications

Melanotan I is FDA-approved for: Erythropoietic protoporphyria (EPP) in adults (Scenesse).

Off-label use should only be pursued under the guidance of a licensed healthcare provider.

Important safety information

Dosage ranges listed above are based on published clinical trial protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.

• Start at the lowest effective dose and titrate up gradually
• Monitor for side effects, especially during dose increases
• Do not exceed researched dose ranges without medical supervision

Research references

• Afamelanotide for Erythropoietic Protoporphyria — New England Journal of Medicine (2015) [PubMed]
• Three-year observational study of afamelanotide in erythropoietic protoporphyria — British Journal of Dermatology (2020) [PubMed]
• Tanning and cutaneous melanin synthesis with subcutaneous melanotan-I and UV exposure — Journal of Investigative Dermatology (2004) [PubMed]